Autism Treatment Market size was valued at USD 28,723.6 million in 2021, growing at a CAGR of 4.9% from 2022 to 2028. The global market provides a detailed overview and that can be segmented by autism type, by treatment approach, and by drug. By autism type, the global autism treatment market has been segmented into Autistic Disorder, Asperger Syndrome, Pervasive Developmental Disorder, and Childhood Disintegrative Disorder. The Autistic Disorder segment is likely to be the largest and fastest-growing segment in terms of type in 2021 due to the high prevalence of this disease. Based on treatment approach, the market is segmented into Behavioural Approaches, Early Intervention, Medication, and Dietary Approach. Among these, the Behavioural Approaches segment is expected to have the fastest-growing market during the forecast period 2022-2028 according to precision business insights. Based on drug, the global autism treatment market is segmented into Risperidone, Aripiprazole, Clozapine, Haloperidol, Sertraline, Methylphenidate, Venlafaxine, Fluoxetine, and Others. The Risperidone segment accounts for the largest share in 2021 and expected to maintain the trend in the upcoming years. It is attributed to increased focus and decreased hyperactivity in the patient. Autism spectrum disorder, or pervasive developmental disorders (PDDs), are neurodevelopmental disorders which is subjective disability in a social association, debilitated correspondence, and stereotyped examples of conduct. The most well-known types of PDD are autistic issue, Asperger’s issue, and unavoidable formative issue not generally indicated (PDD NOS). The increased prevalence of autism is anticipated to create demand for autism treatment market.
In Oct 2022, AXA Health launched neurodiversity services for group PMI
In May 2022, Group launched mobile application for Autism therapy in Nigeria.